EMAIL THIS PAGE TO A FRIEND

Experimental neurology

A re-assessment of long distance growth and connectivity of neural stem cells after severe spinal cord injury.


PMID 24747827

Abstract

As part of the NIH "Facilities of Research Excellence-Spinal Cord Injury" project to support independent replication, we repeated key parts of a study reporting robust engraftment of neural stem cells (NSCs) treated with growth factors after complete spinal cord transection in rats. Rats (n=20) received complete transections at thoracic level 3 (T3) and 2weeks later received NSC transplants in a fibrin matrix with a growth factor cocktail using 2 different transplantation methods (with and without removal of scar tissue). Control rats (n=9) received transections only. Hindlimb locomotor function was assessed with the BBB scale. Nine weeks post injury, reticulospinal tract axons were traced in 6 rats by injecting BDA into the reticular formation. Transplants grew to fill the lesion cavity in most rats although grafts made with scar tissue removal had large central cavities. Grafts blended extensively with host tissue obliterating the astroglial boundary at the cut ends, but in most cases there was a well-defined partition within the graft that separated rostral and caudal parts of the graft. In some cases, the partition contained non-neuronal scar tissue. There was extensive outgrowth of GFP labeled axons from the graft, but there was minimal ingrowth of host axons into the graft revealed by tract tracing and immunocytochemistry for 5HT. There were no statistically significant differences between transplant and control groups in the degree of locomotor recovery. Our results confirm the previous report that NSC transplants can fill lesion cavities and robustly extend axons, but reveal that most grafts do not create a continuous bridge of neural tissue between rostral and caudal segments.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SRP3014 BDNF human, Animal-component free, recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), cell culture tested
1071508
Biotin, United States Pharmacopeia (USP) Reference Standard
C10H16N2O3S
RES1052B-B7
BIOTIN, PharmaGrade, USP, meets FCC testing specifications, Manufactured under appropriate GMP controls for pharma or biopharmaceutical production.
C10H16N2O3S
B3795 Brain-derived neurotrophic factor human, BDNF, recombinant, expressed in E. coli, lyophilized powder, suitable for cell culture
D0731000 Dextran, European Pharmacopoeia (EP) Reference Standard
D0731005 Dextran 1, European Pharmacopoeia (EP) Reference Standard
D0734000 Dextran 10 for calibration, European Pharmacopoeia (EP) Reference Standard
D0737000 Dextran 250 for calibration, European Pharmacopoeia (EP) Reference Standard
D0733000 Dextran 4 for calibration, European Pharmacopoeia (EP) Reference Standard
D0735000 Dextran 40 for calibration, European Pharmacopoeia (EP) Reference Standard
D0738000 Dextran 40 for performance test, European Pharmacopoeia (EP) Reference Standard
D0739000 Dextran 60/70 for performance test, European Pharmacopoeia (EP) Reference Standard
D0736000 Dextran 70 for calibration, European Pharmacopoeia (EP) Reference Standard
D0732000 Dextran Vo, European Pharmacopoeia (EP) Reference Standard
F5542 Fibroblast Growth Factor-Acidic human, FGF-Acidic, recombinant, expressed in E. coli, suitable for cell culture
G1401 Glial Cell Line-derived Neurotrophic Factor from rat, recombinant, expressed in baculovirus infected Sf21 cells, lyophilized powder, suitable for cell culture, ≥97% (SDS-PAGE)
F0291 hBFGF, FGF-Basic, recombinant, expressed in E. coli, suitable for cell culture
N1905 Neurotrophin-3 human, recombinant, expressed in baculovirus infected Sf21 cells, lyophilized powder, suitable for cell culture, >97% (SDS-PAGE)
SRP3267 NT-3 human, Animal-component free, recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC)
SRP3128 NT-3 human, recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), cell culture tested
P3076 Platelet-Derived Growth Factor-AA human, PDGF-AA, recombinant, expressed in E. coli, lyophilized powder, suitable for cell culture
SRP6053 ProBDNF human, recombinant, expressed in E. coli, ≥95% (SDS-PAGE), ≥95% (HPLC)
SRP6052 ProNT-3 human, recombinant, expressed in mammalian cells, ≥95% (SDS-PAGE), ≥95% (HPLC)
SRP0352
TRKC active human, recombinant, expressed in baculovirus infected Sf9 cells, ≥70% (SDS-PAGE)